Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering the genetic medicine. The Boston-based company ...
May 4, 2026 07:29 PM EDT R&D Vertex drops mRNA cystic fibrosis program over 'tolerability' issues Lei Lei Wu News Reporter Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy, after facing challenges delivering the genetic medicine similar to those that have … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that